EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG announces changes in Management Board

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
C.E.O. Interviews


SYGNIS Pharma AG announces changes in Management Board

   Heidelberg,  17 October 2012  -  SYGNIS  Pharma  AG  
  (Frankfurt:   LIOK; ISIN DE000A1E9B74; Prime Standard) announced today that 
Dr. Frank Rathgeb,  Co-CEO/CMO will resign from his office in the Management
Board of the  company by October 31, 2012 in mutual agreement with the
Supervisory Board.

   The retirement of Dr. Rathgeb takes place in  context  with  the  intended
   strategic reorientation of the company after the planned contribution of all
   shares of X-Pol Biotech, S.L., into SYGNIS Pharma AG, with  the  consequence
   that drug development and research in the  field  of  therapeutics  will  no
   longer be in the core focus of the company.

   Ende of adhoc

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             Stuttgart, regulated dealing/prime standard: Frankfurt 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: